Program
Vonorasan fumarate injection1
Its studies are mostly in Peptic Ulcer Hemorrhage, led by Lunan Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Lunan Pharmaceutical Group | 11 open or running | phase 2since Jan 14, 2025 | Jan 14, 2025 | Feb 2027phase 2 · NCT06783257 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 14, 2025First study: phase 2 study in Peptic Ulcer HemorrhageFirst studyNCT06783257 · 150 planned
Ahead
- Feb 2027Primary completion: phase 2 study in Peptic Ulcer HemorrhageNCT06783257
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06783257Peptic Ulcer Hemorrhage | 2 | Not yet recruiting | Feb 2027 | 150 |
How it is read
Names in the registry
- “Vonorasan fumarate injection1”, 1 entry
Conditions, from the studies’ own filings
- Peptic Ulcer Hemorrhage, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.